Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HBV infection, defined as positive serum HBsAg for at least 6 months or HBsAg positive \> 3 months and positive for immunoglobulin G antibody against hepatitis B core antigen~* 18 through 69 years of age, inclusive~* Hepatitis B e antigen (HBeAg) positive~* HBV DNA ≥ 10\^8 copies/mL~* ALT ≤ the upper limit of the normal range (ULN)~* Willing and able to provide written informed consent~* Negative serum beta-human chorionic gonadotropin (for females of childbearing potential only)~* Calculated creatinine clearance ≥ 70 mL/min~* Hemoglobin ≥ 10 g/dL~* Neutrophils ≥ 1,500/mm\^3~* No prior oral HBV therapy (eg, nucleotide and/or nucleoside therapy or other investigational agents for HBV infection)~Exclusion Criteria:~* Pregnant women, women who were breast feeding, or who believed they may have wished to become pregnant during the course of the study~* Males and females of reproductive potential unwilling to use an effective method of contraception during the study~* Decompensated liver disease defined as direct (conjugated) bilirubin \> 1.2 x ULN, prothrombin time \> 1.2 x ULN, platelets \< 150,000/mm\^3, serum albumin \< 3.5 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, or variceal hemorrhage)~* Received interferon (pegylated or not) therapy within 6 months of the screening visit~* Alpha-fetoprotein \> 50 ng/mL~* Evidence of hepatocellular carcinoma~* Coinfection with hepatitis C virus (by serology), HIV, or hepatitis D virus~* Significant renal, cardiovascular, pulmonary, or neurological disease~* Received solid organ or bone marrow transplantation~* Was currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion~* Had proximal tubulopathy~* Known hypersensitivity to the study drugs, the metabolites, or formulation excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Tenofovir DF (Type: EXPERIMENTAL): Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
- FTC+Tenofovir DF (Type: EXPERIMENTAL): Participants were randomized to receive FTC plus tenofovir DF once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).